The global ruminant vaccines market size is estimated to reach USD 7.02 billion by 2030, expanding at a CAGR of 7.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing demand for animal protein, the prevalence of infectious diseases in ruminants, the rising livestock trade, and R&D advancements. In December 2022, Virbac, a key market player, expanded its capabilities with the inauguration of a new R&D center in Taiwan, in response to the growing demand for veterinary vaccines. This has enabled the company to develop innovative solutions and immune stimulants and/or enhance existing products on a domestic, regional, and global level.
The COVID-19 pandemic notably impacted the market for ruminant vaccines. This included disruptions in the supply chain, reduced access to veterinary services, impact on trade and exports, and economic constraints on farmers. For example, in 2020, Indian Immunologicals Ltd reported decreased trade, exports, and institutional businesses due to the pandemic. Despite this, the company continued to be the largest supplier of FMD vaccines in India. Furthermore, the economic slowdown of 2022 also significantly affected the market. Merck & Co., Inc. for instance, reported that livestock product sales were practically flat in 2022. This was attributed to the unfavorable impact of foreign exchange.
Support from governments, regulatory authorities, and animal health organizations drives the adoption of ruminant vaccines. All these institutions worldwide have recognized the importance of preventing and controlling animal diseases. They have implemented various initiatives and regulations to promote the use of vaccines in the ruminant sector. These initiatives include awareness campaigns, vaccination programs, and subsidies or incentives for farmers to vaccinate their animals. For instance, the World Organization for Animal Health manages vaccine banks to ensure the procurement of high-quality vaccines, facilitate economies of scale, and contribute to harmonizing global and regional control programs. As of January 2023, the organization manages 2 active vaccine banks focusing on peste des petits ruminants (PPR) and rabies.
Request a free sample copy or view report summary: Ruminant Vaccines Market Report
The cattle segment dominated the market, based on animal type, in 2024. The sheep & goats segment is projected to expand at the highest CAGR of 10.0% over the projection period
By vaccine type, the modified/ attenuated live vaccines segment contributed to the largest share of over 51.7% in 2024. The other vaccines segment, on the other hand, is anticipated to grow the fastest at a rate of 10.33% in the coming years
In 2024, based on indication, Bovine Respiratory Diseases (BRD) accounted for the highest share of around 34.3% of the market. The other indications segment is expected to grow at the fastest rate of over 10.1% during the forecast period
In terms of route of administration, the injectable segment dominated the market in 2024 and is expected to grow at a significant CAGR during the forecast period, while the intranasal segment is expected to grow at the fastest CAGR over the forecast period.
In 2024, North America accounted for the highest regional share of more than 37.74% of the market. Asia Pacific is anticipated to advance at a growth rate of about 9.0% owing to the thriving dairy and beef sector in key markets of the region
International trade of livestock and animal products has been increasing due to globalization and changing dietary preferences. However, the movement of animals across borders can also facilitate the spread of infectious diseases. To mitigate this risk, countries and trade organizations enforce strict import and export regulations, including vaccination requirements, driving the demand for ruminant vaccines to ensure compliance with trade regulations
Grand View Research has segmented the global ruminant vaccines market based on animal type, vaccine type, indication, route of administration, distribution channel, and region:
Ruminant Vaccines Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
Cattle
Sheep & Goats
Ruminant Vaccines Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030)
Modified/ Attenuated Live
Inactivated (Killed)
Other Vaccines
Ruminant Vaccines Indication Outlook (Revenue, USD Million, 2018 - 2030)
BVD Infection
Bovine Respiratory Diseases (BRD)
Leptospirosis
Clostridial diseases
Diarrhea/ Scours
FMD
Other Indications
Ruminant Vaccines Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Injectable
Intranasal
Ruminant Vaccines Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Retail
E-Commerce
Hospital/Clinic Pharmacies
Ruminant Vaccines Regional Outlook (Revenue, USD Million, 2018 -2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Ruminant Vaccines Market
Boehringer Ingelheim International GmbH
Zoetis Services LLC
Vaxxinova International BV
Merck & Co., Inc.
Bimeda Animal Health Ltd.
Indian Immunologicals Ltd.
Elanco
Virbac
Ceva Santé Animale
CZ Vaccines S.A.U. (Zendal Group)
"The quality of research they have done for us has been excellent..."